Aprepitant as add-on to standard antiemetic regimen for concurrent chemoradiotherapy induced nausea vomiting in head and neck cancer

Table 5 Adverse events reported in the two study groups, n (%)

Symptoms	Group A	Group B	P value
Reduced appetite	19 (44.1)	28 (65.1)	0.52
Abdominal discomfort	16 (37.2)	17 (39.5)	0.82
Generalized weakness	9 (20.9)	7 (16.2)	0.58
Constipation	8 (18.6)	12 (27.9)	0.31
Headache	6 (13.9)	5 (11.6)	0.75
Diarrhoea	4 (9.3)	7 (16.2)	0.33
Abdominal discomfort with flatulence	3 (6.9)	4 (9.3)	0.69
Dizziness	3 (6.9)	1 (2.3)	0.31
Ghabrahat	0 (0.0)	2 (4.6)	0.15